E Fund HK Launches the E Fund (HK) Solactive Biopharma Select Index ETF Tracking the Solactive Biopharma Select Index

FRANKFURT AM MAIN – Solactive is pleased to announce its continued collaboration with E Fund Management (Hong Kong) Co., Limited (“E Fund HK”) on the launch of the E Fund (HK) Solactive Biopharma Select Index ETF, which tracks the Solactive Biopharma Select Index. The ETF is listed on the Hong Kong Stock Exchange (HKEX) and is designed to track the performance of biopharmaceutical companies listed in the United States and Hong Kong.

The biopharmaceutical sector continues to be supported by structural drivers such as aging populations, increasing healthcare demand, and ongoing innovation in biotechnology, gene therapies, and precision medicine. At the same time, Hong Kong has strengthened its role as an important listing venue for Chinese biotechnology companies, while the United States remains a global center for pharmaceutical innovation. By combining these two markets, the index reflects a globally relevant segment of the healthcare sector.

The Solactive Biopharma Select Index comprises 100 constituents drawn from eligible U.S.- and Hong Kong-listed biopharmaceutical securities. From this universe, up to 30 Hong Kong-listed securities and at least 70 U.S.-listed securities are selected based on total market capitalization and liquidity requirements. Constituents are equally weighted within their respective regions, with an aggregate regional allocation of 65% Hong Kong-listed securities and 35% U.S.-listed securities. The index is rebalanced semi-annually. By combining Hong Kong-listed biotechnology companies with established U.S. biopharmaceutical companies, the index represents the global drug development ecosystem and provides diversified exposure to companies operating across the sector.

Timo Pfeiffer, Chief Markets Officer at Solactive, commented: “We are pleased to continue our cooperation with E Fund with the launch of the E Fund Solactive Biopharma Select Index ETF. The biopharmaceutical sector remains an important area of innovation within global healthcare, and this index provides a rules-based and transparent representation of companies operating in this segment.”

Sharon Wang, Chief Executive Officer of E Fund HK, commented: “We are very pleased with the successful launch of the E Fund (HK) Solactive Biopharma Select Index ETF. The Index is designed to reflect the performance of leading companies in the global biopharmaceutical field. It is currently the world's only global biopharma index spanning both the Hong Kong and US stock markets. By bridging the world's leading centers of R&D and its largest consumer market, the Index provides single-access exposure to 100 renowned, cutting-edge biopharmaceutical companies from China, the US, Europe, and other regions worldwide, making it a rare tool for capturing investment opportunities amid the globalization of the industry.”